Huanghai Pharmaceutical To Set Up RMB 100 Million Production Base
This article was originally published in PharmAsia News
Executive Summary
Qingdao Huanghai Pharmaceutical, China's only pharmaceutical company to have more than five products in sustained- and controlled-release technology, has begun construction of its phase two pharmaceutical high-tech industrial park program. At a total investment of more than RMB 100 million, the project is built according to GMP requirements with 8,000 square meters of factory floor space and 4,000 square meters of auxiliary warehouse. Scheduled for operation this October, the plant can produce 2.5 billion sustained- and controlled-release tablets. According to Huanghai officials, R&D and innovation will represent the fundamental tenet of the base. The firm will continue to improve its sustained-release technology platform in the next two years and develop pulsed, targeted-drug administration. (Click here for more - Chinese language)